| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/HEP.21090 |
| P698 | PubMed publication ID | 16496308 |
| P50 | author | José A. Carrión | Q47153942 |
| Jaime Bosch | Q61107953 | ||
| Miquel Navasa | Q68012695 | ||
| Xavier Forns | Q88169793 | ||
| Juan Carlos García-Pagan | Q43139923 | ||
| P2093 | author name string | Antoni Rimola | |
| Rosa Miquel | |||
| Miquel Bruguera | |||
| Alejandro Blasco | |||
| Rosa Gilabert | |||
| Juan-Carlos García-Valdecasas | |||
| P2860 | cites work | Sampling variability of liver fibrosis in chronic hepatitis C. | Q48583601 |
| The nomenclature of chronic hepatitis: time for a change | Q48793790 | ||
| Low-dose midazolam sedation: an option for patients undergoing serial hepatic venous pressure measurements. | Q51091239 | ||
| Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. | Q51545030 | ||
| Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. | Q52941932 | ||
| Hepatitis C recurrence is more severe after living donor compared to cadaveric liver transplantation | Q57757053 | ||
| Portal hypertension | Q69504006 | ||
| Portal pressure, presence of gastroesophageal varices and variceal bleeding | Q69868227 | ||
| Transjugular liver biopsy in the 1990s: a 2-year audit | Q77417809 | ||
| Evolution of liver transplantation in Europe: report of the European Liver Transplant Registry | Q34277755 | ||
| Assessment of therapeutic benefit of antiviral therapy in chronic hepatitis C: is hepatic venous pressure gradient a better end point? | Q34526034 | ||
| Host and donor risk factors before and after liver transplantation that impact HCV recurrence | Q35572054 | ||
| The hepatic venous pressure gradient: anything worth doing should be done right | Q35651680 | ||
| Classification of chronic viral hepatitis: a need for reassessment | Q37032966 | ||
| HCV-related fibrosis progression following liver transplantation: increase in recent years | Q41732518 | ||
| The association between hepatitis C infection and survival after orthotopic liver transplantation | Q42672810 | ||
| Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials | Q42990077 | ||
| High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. | Q42991412 | ||
| Hepatitis C virus kinetics during and immediately after liver transplantation. | Q43036834 | ||
| A model to predict severe HCV-related disease following liver transplantation. | Q43047851 | ||
| Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. | Q43049480 | ||
| Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy | Q43693273 | ||
| Sources of variability in histological scoring of chronic viral hepatitis | Q43816595 | ||
| Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model | Q44151781 | ||
| Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. | Q44385938 | ||
| A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. | Q44527614 | ||
| Long-term outcome of liver transplants for chronic hepatitis C: a 10-year follow-up | Q44741810 | ||
| Improved prediction of fibrosis in chronic hepatitis C using measures of insulin resistance in a probability index | Q44880241 | ||
| Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study | Q45737816 | ||
| Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation | Q45740469 | ||
| Wedged hepatic venous pressure adequately reflects portal pressure in hepatitis C virus-related cirrhosis | Q45746115 | ||
| Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group | Q45747079 | ||
| Prediction of fibrosis in HCV-infected liver transplant recipients with a simple noninvasive index. | Q46388769 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hepatitis C | Q154869 |
| P304 | page(s) | 492-499 | |
| P577 | publication date | 2006-03-01 | |
| P1433 | published in | Hepatology | Q15724398 |
| P1476 | title | Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation | |
| P478 | volume | 43 |
| Q33394104 | A review of the treatment of chronic hepatitis C virus infection in cirrhosis |
| Q83099911 | Back to the future with noninvasive biomarkers of liver fibrosis |
| Q90253521 | Band ligation versus beta-blockers for primary prophylaxis of oesophageal variceal bleeding in children with chronic liver disease or portal vein thrombosis |
| Q38366999 | Circulating CO3-610, a degradation product of collagen III, closely reflects liver collagen and portal pressure in rats with fibrosis. |
| Q82307815 | Comparison of balloon vs. straight catheter for the measurement of portal hypertension |
| Q39868791 | Computer-assisted image analysis of liver collagen: relationship to Ishak scoring and hepatic venous pressure gradient. |
| Q37317654 | Current and future anti-fibrotic therapies for chronic liver disease |
| Q22299427 | Current management and perspectives for HCV recurrence after liver transplantation |
| Q30355947 | Diagnosis of cirrhosis and portal hypertension: imaging, non-invasive markers of fibrosis and liver biopsy. |
| Q41840433 | Dialysis reduces portal pressure in patients with chronic hepatitis C. |
| Q40568564 | Fibrosing Cholestatic Hepatitis in a Complicated Case of an Adult Recipient After Liver Transplantation: Diagnostic Findings and Therapeutic Dilemma. |
| Q28076406 | Fibrosing cholestatic hepatitis C in post-transplant adult recipients of liver transplantation |
| Q52577714 | Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection. |
| Q38334016 | Hagen-Poiseuille's law: The link between cirrhosis, liver stiffness, portal hypertension and hepatic decompensation |
| Q53581215 | Hepatic fibrosis 2006: report of the Third AASLD Single Topic Conference. |
| Q84331259 | Hepatic venous pressure gradient in 2010: optimal measurement is key |
| Q37711328 | Hepatic venous pressure gradient: clinical use in chronic liver disease |
| Q37313977 | Hepatic venous pressure gradient: worth another look? |
| Q43040802 | Hepatitis C virus and human immunodeficiency virus: the un-won battle |
| Q34860505 | Hepatitis C virus receptors claudin-1 and occludin after liver transplantation and influence on early viral kinetics. |
| Q38408888 | Hepatitis C virus reinfection after liver transplant: New chances and new challenges in the era of direct-acting antiviral agents |
| Q26999368 | Hepatitis C: New challenges in liver transplantation |
| Q40856213 | Impact of Donor and Recipient Single Nucleotide Polymorphisms in Living Liver Donor Transplantation for Hepatitis C. |
| Q26781331 | Interferon-Free Hepatitis C Treatment before and after Liver Transplantation: The Role of HCV Drug Resistance |
| Q30439743 | Invasive and non-invasive diagnosis of cirrhosis and portal hypertension |
| Q26825287 | Invasive and non-invasive techniques for detecting portal hypertension and predicting variceal bleeding in cirrhosis: a review |
| Q51836024 | KASL clinical practice guidelines: management of hepatitis C. |
| Q34282455 | Lack of a 5.9 kDa peptide C-terminal fragment of fibrinogen α chain precedes fibrosis progression in patients with liver disease |
| Q83395480 | Liver biopsy |
| Q26826920 | Liver biopsy in modern clinical practice: a pediatric point-of-view |
| Q90664867 | Liver graft rejection following immune checkpoint inhibitors treatment: a review |
| Q50594991 | Liver stiffness identifies two different patterns of fibrosis progression in patients with hepatitis C virus recurrence after liver transplantation. |
| Q58704499 | Liver transplantation and hepatitis C |
| Q26773224 | Liver transplantation for viral hepatitis in 2015 |
| Q26781741 | Management of Hepatitis C Post-liver Transplantation: a Comprehensive Review |
| Q26797581 | Management of Hepatocellular Carcinoma in Cirrhotic Patients with Portal Hypertension: Relevance of Hagen-Poiseuille's Law |
| Q38395275 | Management of post transplant hepatitis C in the direct antiviral agents era. |
| Q43063071 | Monitoring hepatitis C infection in the liver allograft |
| Q37015805 | New perspectives for preventing hepatitis C virus liver graft infection |
| Q55437493 | Noninvasive Assessment of Portal Hypertension in Advanced Chronic Liver Disease: An Update. |
| Q83258968 | Noninvasive assessment of liver fibrosis |
| Q37676132 | Now there are many (stages) where before there was one: In search of a pathophysiological classification of cirrhosis |
| Q81149790 | Portal hypertension and variceal bleeding--unresolved issues. Summary of an American Association for the study of liver diseases and European Association for the study of the liver single-topic conference |
| Q88636602 | Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases |
| Q91741789 | Portal pressure monitoring-state-of-the-art and future perspective |
| Q38229320 | Recurrent HCV after liver transplantation-mechanisms, assessment and therapy |
| Q37017909 | Safety, Efficacy, and Tolerability of Sofosbuvir and Ribavirin in Management of Recurrent Hepatitis C Virus Genotype 4 After Living Donor Liver Transplant in Egypt: What Have We Learned so far? |
| Q44760467 | Serum markers of liver fibrosis in patients with chronic hepatitis C infection. Prognostic value of noninvasive markers of fibrosis in liver transplantation |
| Q59359559 | Severe Hepatitis C Recurrence as a Risk Factor for Opportunistic Infections in Liver Transplant Recipients |
| Q41564280 | Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation |
| Q35237338 | Staging of liver fibrosis or cirrhosis: The role of hepatic venous pressure gradient measurement |
| Q37078109 | Technology Insight: noninvasive assessment of liver fibrosis by biochemical scores and elastography. |
| Q41112424 | The Molecular Basis of Portal Hypertension |
| Q37590666 | The clinical use of HVPG measurements in chronic liver disease |
| Q37784847 | The relationship between liver disease stage and liver fibrosis: a tangled web |
| Q40072990 | The relationship between transient elastography and histological collagen proportionate area for assessing fibrosis in chronic viral hepatitis. |
| Q45385243 | Treatment for recurrent hepatitis C virus infection after liver transplantation |
| Q35790393 | Treatment of chronic hepatitis C in liver transplant candidates and recipients: Where do we stand? |
| Q82640107 | Wedged hepatic vein pressure (WHVP): ready for prime time |
| Q38976820 | When and How to Treat HCV Infection with the New Antivirals before or after Liver Transplantation |
| Q46015372 | [Liver diseases]. |
| Q26864647 | Μanagement of patients with hepatitis B and C before and after liver and kidney transplantation |
Search more.